ANCO's Hematologic Malignancies Update 2022

The faculty will present the latest research on treatment modalities for hematologic malignancies—leukemias, lymphomas, and myeloma—along with case studies for these diagnoses.

The program takes place in :

Sacramento on September 17th

San Francisco on November 12th

Registration and continental breakfast will be available at 8:00 am; presentations begin at 9 am. The program will conclude by 12:30pm.

ANCO acknowledges the support of Adaptive Biotechnologies, ADC Therapeutics,  Amgen, Beigene, Incyte Corporation, Kite Pharma, Merck, Sanofi Aventis, SeaGen, and Secura Bio in making this program possible.

Attendance is limited to the first 50 health care professionals per location.